Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies (Q33403607)

26 July 2017

title

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies (English)

1 reference

Véronique Frémeaux-Bacchi

26 July 2017

author

5

object named as

Véronique Frémeaux-Bacchi

1 reference

26 July 2017

Lubka T Roumenina

3

0 references

author name string

Julien Zuber

1

1 reference

26 July 2017

Fadi Fakhouri

2

1 reference

26 July 2017

Chantal Loirat

4

1 reference

26 July 2017

French Study Group for aHUS/C3G

6

1 reference

26 July 2017

language of work or name

English

0 references

publication date

2 October 2012

1 reference

Nature Reviews Nephrology

26 July 2017

published in

1 reference

26 July 2017

volume

8

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

643-657

1 reference

C3 glomerulopathy: a new classification

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Alternative complement pathway assessment in patients with atypical HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Membranoproliferative glomerulonephritis--a new look at an old entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Placental transport of immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Management of paroxysmal nocturnal haemoglobinuria: a personal view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Structures of C3b in complex with factors B and D give insight into complement convertase formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

The development of atypical hemolytic uremic syndrome depends on complement C5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Early treatment with eculizumab in atypical haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

New insights into postrenal transplant hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab and renal transplantation in a patient with CAPS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Management of hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Thrombotic microangiopathies: new insights and new challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

How I treat patients with thrombotic thrombocytopenic purpura: 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab in severe Shiga-toxin-associated HUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Complement activation in thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Complement Mutation-AssociatedDe NovoThrombotic Microangiopathy Following Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Advances in understanding of pathogenesis of aHUS and HELLP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Complications of apheresis in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Myocardial infarction is a complication of factor H-associated atypical HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Proximal cerebral artery stenosis in a patient with hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Complement activation and interleukin response in major abdominal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Molecular mechanisms of inflammation and tissue injury after major trauma--is complement the "bad guy"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Hemolytic uremic syndrome recurrence after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab for dense deposit disease and C3 glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab in a patient with dense-deposit disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab and Refractory Membranoproliferative Glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab for the Treatment of Dense-Deposit Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Pathology after eculizumab in dense deposit disease and C3 GN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

The role of complement inhibition in PNH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Indications for the immunological evaluation of patients with meningitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Renal and neurological involvement in typical Shiga toxin-associated HUS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

correspondence: Pregnancy in PNH: another eculizumab baby

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.214

Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011.

31 March 2020

1 reference

12 December 2020

Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity

1 reference

12 December 2020

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

1 reference

12 December 2020

Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.214

1 reference

26 July 2017

1 reference